

## Policies Repository



# AmeriHealth.

**Policy Title** Modafinil (Provigil®)

**Policy Number** FS.CLIN.18

**Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification and age, gender or quantity restrictions. Individual member benefits must be verified.**

**This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage.**

**Members are advised to use participating pharmacies in order to receive the highest level of benefits.**

<b>Policy</b>	<p><b>Modafinil (Provigil®)</b> is indicated to improve wakefulness in individuals with excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.</p> <p>The use of modafinil (Provigil®) requires prior authorization (i.e. clinical pharmacy and/or medical director review). An urgent, temporary, 96-hour supply is available (through retail pharmacy facilitation) upon request during review for medical necessity.</p>
<b>Policy description</b>	<p><b>Modafinil (Provigil®)</b> is a wakefulness-promoting agent. Modafinil (Provigil®) is chemically unrelated to the traditional central nervous system (CNS) stimulants amphetamine and methylphenidate, and has a pharmacologic profile different from that of sympathomimetic amines. Although the precise mechanism of action is unknown, modafinil (Provigil®) promotes wakefulness by selectively increasing neuronal activation in discrete regions of the brain (eg, anterior hypothalamus) that are believed to be involved in mediating normal wakefulness. Modafinil (Provigil®) is not indicated for use in circadian rhythm sleep disorders or other sleep deprivation disorders.</p>
<b>Policy guideline inclusion</b>	<p><b><u>NARCOLEPSY</u></b> <b>Modafinil (Provigil®)</b> is approved when the following inclusion criterion is met:</p> <ul style="list-style-type: none"><li>• Documentation of a diagnosis of Narcolepsy with recommendation of modafinil (Provigil®) by a neurologist or sleep specialist</li></ul> <p><b><u>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS)</u></b> <b>Modafinil (Provigil®)</b> is approved when <b>both</b> of the following inclusion criteria are met:</p> <ul style="list-style-type: none"><li>• Documentation of a diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS)</li><li>• Documentation that modafinil (Provigil®) will be used concurrently with</li></ul>

continuous positive airway pressure (CPAP)

**SHIFT WORK SLEEP DISORDER (SWSD)**

**Modafinil (Provigil®)** is approved when **all** of the following inclusion criteria are met:

- Member meets **one** of the following:
  - Documentation of a diagnosis of Shift Work Sleep Disorder with recommendation of modafinil (Provigil®) by a neurologist or sleep specialist
  - Polysomnography and the multiple sleep latency test (MSLT) demonstrate loss of a normal sleep-wake pattern
- No medical or mental disorder accounts for the symptoms
- The symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g. time-zone change [jet lag] syndrome)

**Policy guideline exclusion**

**NARCOLEPSY**

**Modafinil (Provigil®)** is denied when the following exclusion criterion is present:

- No documentation of a diagnosis of Narcolepsy with recommendation of modafinil (Provigil®) by a neurologist or sleep specialist

**OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS)**

**Modafinil (Provigil®)** is denied when **either** of the following exclusion criteria is present:

- No documentation of a diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS)
- No documentation that modafinil (Provigil®) will be used concurrently with continuous positive airway pressure (CPAP)

**SHIFT WORK SLEEP DISORDER (SWSD)**

**Modafinil (Provigil®)** is denied when **either** of the following exclusion criteria is present:

- Member does not meet **one** of the following:
  - Documentation of a diagnosis of Shift Work Sleep Disorder with recommendation of modafinil (Provigil®) by a neurologist or sleep specialist
  - Polysomnography and the multiple sleep latency test (MSLT) demonstrate loss of a normal sleep-wake pattern
- A medical or mental disorder accounts for the symptoms
- The symptoms meet criteria for other sleep disorder producing insomnia or excessive sleepiness (e.g. time-zone change [jet lag] syndrome).

**Policy List of Applicable Drugs**

Brand Name	Generic Name
Provigil	Modafinil

**Dosing and administration**

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

**Policy references**

Narcolepsy. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000:609-615.

ICSD-international classification of sleep disorders: diagnostic and coding manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005

Robert L Sack, MD; Dennis Auckley, MD; R. Robert Auger, MD; Mary A. Carskadon, PhD; Kenneth P. Wright Jr, PhD; Michael V. Vitiello, PhD; Irina V. Zhdanova, MD. Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders An American Academy of Sleep Medicine Review. SLEEP, Vol. 30, No. 11, 2007

Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, Boehlecke B, Chesson AL Jr, Friedman L, Maganti R, Owens J, Pancer J, Zak R, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007 Dec 1;30(12):1705-11. [35 references]

American Sleep Disorders Association, Diagnostic Classification Steering Committee. *International Classification of Sleep Disorders: Diagnostic and Coding Manual*. Rochester, MN: American Academy of Sleep Medicine; 1990.

Cephalon, Inc. Provigil® (modafinil) Tablets [C-IV] Rx Only [package insert]. [Provigil Web site]. 10/2010. Available at: [http://www.provigil.com/media/PDFs/prescribing\\_info.pdf](http://www.provigil.com/media/PDFs/prescribing_info.pdf). Accessed May 16, 2011.

Chokroverty S. Abnormal sleep: idiopathic central nervous system hypersomnia. In: Kryger MH, Roth T, Dement WC. *Principles and Practice of Sleep Medicine*. 3rd ed. Philadelphia, PA: WB Saunders; 2000: 689-691.

Czeisler CA. Modafinil for the treatment of excessive sleepiness in chronic shift work disorder. Sleep. 2003;26:A114.

DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2003;64:1057-1064.

DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. *J Clin Psychopharmacol*. 2004;24:87-90.

Lippincott Williams & Wilkins, Inc. *Drug Facts and Comparisons*. [Provigil e-facts]. Available at: <http://www.factsandcomparisons.com>. Accessed May 16, 2011.

Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. *J Clin Psychopharmacol*. 2003;23:207-209.

Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. *J Clin Psychiatry*. 2004;65:414-420.

---

**Policy link to related policies**

**Version effective date**

06/09/2011

---

The Policy Bulletins on this web site were developed to assist AmeriHealth in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an AmeriHealth member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. AmeriHealth does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of AmeriHealth. If you have a specific medical condition, please consult with your doctor. AmeriHealth reserves the right at any time to change or update its Policy Bulletins. ©2011 AmeriHealth, Inc. All Rights Reserved.

